Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years due to the United States' request for sensitive biological samples.
This rejection came to light after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government representative has since stated that the United States was requesting health data for research and commercial gain but was unwilling to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for continued dialogue to reach a deal agreeable to both sides so the country's vital HIV programme can be sustained.
Broader Background
This development comes after a similar situation in Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date signed similar agreements, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research with no certainty that the resulting innovations would be accessible to our citizens if a future health crisis arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending systems already established through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be arranged in a way that respects the sovereignty and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but suggested that talks need to persist given that much of the country's HIV programmes were funded by international support.
"If technical issues arise, including those involving data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," it added.
The halted deal highlights the continuing challenges between receiving much-needed international aid and protecting local interests in an increasingly data-driven world.